The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study.

Published

Journal Article (Review)

PURPOSE OF REVIEW: Biomarker-guided management of patients with chronic heart failure with reduced ejection fraction (HFrEF) remains controversial. RECENT FINDINGS: Biomarkers have established roles for diagnosis and prognostication in HF. Pilot data suggested that use of natriuretic peptides might be helpful to guide HF care. The recent Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) randomized-controlled trial did not find therapy guided by NT-proBNP to be more effective than usual care in improving the primary endpoint of HF hospitalization or cardiovascular mortality amongst patients with chronic HFrEF. Patients in GUIDE-IT received similar care and had similar NT-proBNP lowering regardless of treatment allocation. Though biomarkers retain important standing for diagnosis and prognosis in HF, the GUIDE-IT trial results suggest carefully managed patients may not benefit from a biomarker-guided strategy. Future studies focusing this intervention on patients treated in a more real-world setting are needed.

Full Text

Duke Authors

Cited Authors

  • Ibrahim, NE; Januzzi, JL

Published Date

  • April 2018

Published In

Volume / Issue

  • 15 / 2

Start / End Page

  • 37 - 43

PubMed ID

  • 29468530

Pubmed Central ID

  • 29468530

Electronic International Standard Serial Number (EISSN)

  • 1546-9549

Digital Object Identifier (DOI)

  • 10.1007/s11897-018-0381-0

Language

  • eng

Conference Location

  • United States